REG - Indivior PLC - Indivior to Host Capital Markets Day December 7

IndiviorAnnouncement

09/11/2022 08:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221109:nRSI7168Fa&default-theme=true

RNS Number : 7168F  Indivior PLC  09 November 2022

 

 

Indivior to Host Capital Markets Day December 7, 2022 in New York City

Slough, UK, and Richmond, VA, November 9, 2022 - Indivior PLC (LON: INDV)
today announced that it will be hosting a Capital Markets Day on Wednesday,
December 7, 2022, in New York City.  The event will be hosted by Mark
Crossley, Chief Executive Officer, along with members of the Indivior
executive leadership team. The focus of the event will be detailing the
company's strategic growth plans and roadmap for delivering long-term
shareholder value.

 

The event will begin at 8:30 am EST and conclude at 12:30 pm EST. Due to
seating capacity, in-person participation is limited to institutional
investors and analysts.

 

For those wishing to attend in person, please RSVP to
investorrelations@indivior.com and further location details will be provided.
Remote participants will have the ability to ask questions.

 

Further details about the Capital Markets Day can be found at cmd.indivior.com
(https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.indivior.com%2Fen%2Finvestors%2Fcapital-markets-day&data=05%7C01%7Ctimothy.owens%40Indivior.com%7Caaa09a2376964a82cf3808dab8e1606d%7Cbed52191489442999db948e4fb29646e%7C1%7C0%7C638025575432590096%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=XG8xEVGLdU08fstzaobMJ3HnUEoT%2Blc2%2FVkC%2FumuKO4%3D&reserved=0)
.

 

To access the live webcast, please click INDV CMD 2022
(https://wsw.com/webcast/cc/indv.l/1540962) .

 

A webcast replay will be available after the event has concluded.

 

About Indivior

Indivior is a global pharmaceutical company working to help change patients'
lives by developing medicines to treat substance use disorders (SUD) and
serious mental illnesses. Our vision is that all patients around the world
will have access to evidence-based treatment for the chronic conditions and
co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from
a global human crisis to a recognized and treated chronic disease. Building on
its global portfolio of OUD treatments, Indivior has a pipeline of product
candidates designed to both expand on its heritage in this category and
potentially address other chronic conditions and co-occurring disorders of
SUD, including alcohol use disorder and cannabis use disorder. Headquartered
in the United States in Richmond, VA, Indivior employs approximately 1,000
individuals globally and its portfolio of products is available in over 40
countries worldwide. Visit www.indivior.com
(https://nam12.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.indivior.com%2F&data=04%7C01%7Cjason.thompson%40Indivior.com%7C50524c1bfa284722f7ee08da13118474%7Cbed52191489442999db948e4fb29646e%7C1%7C0%7C637843263192018647%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000&sdata=XV57BWLOjOnGhAQJWI0WKEK4%2FXf0M9QcOEiYwwerqho%3D&reserved=0)
to learn more. Connect with Indivior on LinkedIn by visiting
www.linkedin.com/company/indivior
(https://nam12.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.linkedin.com%2Fcompany%2Findivior&data=04%7C01%7Cjason.thompson%40Indivior.com%7C50524c1bfa284722f7ee08da13118474%7Cbed52191489442999db948e4fb29646e%7C1%7C0%7C637843263192018647%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000&sdata=ztGNJPoRRJvCmxgR2tqSP1oJuDdNpAGH7hPFUtuOHcA%3D&reserved=0)
.

 

Contact:

Jason Thompson

Vice President, Investor Relations

Tel: 804-402-7123 or jason.thompson@indivior.com
(mailto:jason.thompson@indivior.com)

 

Tim Owens

Director, Investor Relations

Tel: 804-263-3978 or timothy.owens@indivior.com
(mailto:timothy.owens@indivior.com)

 

-ends-

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEADFPESPAFFA